We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

53 hedge funds and large institutions have $21.6M invested in Applied Therapeutics in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 20 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

10.73% more ownership

Funds ownership: 47.1%57.83% (+11%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

13% less call options, than puts

Call options by funds: $14K | Put options by funds: $16K

17% less capital invested

Capital invested by funds: $26M → $21.6M (-$4.45M)

25% less funds holding

Funds holding: 7153 (-18)

30% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 20

62% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 26

Holders
53
Holders Change
-18
Holders Change %
-25.35%
% of All Funds
0.89%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
14
Reduced
20
Closed
26
Calls
$14K
Puts
$16K
Net Calls
-$2K
Net Calls Change
+$33K
Name Holding Trade Value Shares
Change
Change in
Stake
BCM
26
Bridgeway Capital Management
Texas
$56K -$81.9K -50,000 -46%
MS
27
Maven Securities
Jersey
$47K +$81.9K +50,000 New
Acadian Asset Management
28
Acadian Asset Management
Massachusetts
$45K +$22.1K +13,487 +40%
Dimensional Fund Advisors
29
Dimensional Fund Advisors
Texas
$35K -$3.85K -2,349 -6%
AG
30
Algert Global
California
$35K +$14.3K +8,740 +31%
Northern Trust
31
Northern Trust
Illinois
$34K -$211K -128,792 -78%
UBS Group
32
UBS Group
Switzerland
$24K +$6.3K +3,850 +17%
BNP Paribas Financial Markets
33
BNP Paribas Financial Markets
France
$21.8K +$35.1K +21,415 +1,391%
Qube Research & Technologies (QRT)
34
Qube Research & Technologies (QRT)
United Kingdom
$16K +$28.4K +17,370 New
Goldman Sachs
35
Goldman Sachs
New York
$15K -$129K -78,530 -83%
AQR Capital Management
36
AQR Capital Management
Connecticut
$13K -$117K -71,157 -84%
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$12K +$21.4K +13,076 New
TRCT
38
Tower Research Capital (TRC)
New York
$10K +$7.86K +4,799 +82%
Citigroup
39
Citigroup
New York
$9K +$10.3K +6,276 +224%
Simplex Trading
40
Simplex Trading
Illinois
$6K -$1.52K -929 -12%
O
41
OrbiMed
New York
$4.03K +$6.96M +4,250,000 New
Bank of America
42
Bank of America
North Carolina
$4K -$25.9K -15,796 -78%
CSS
43
Cubist Systematic Strategies
Connecticut
$4K
AA
44
Ancora Advisors
Ohio
$2K
JP Morgan Chase
45
JP Morgan Chase
New York
$1K -$16.9K -10,328 -89%
Group One Trading
46
Group One Trading
Illinois
$1K -$164 -100 -8%
FDCDDQ
47
Federation des caisses Desjardins du Quebec
Quebec, Canada
$80
Bank of New York Mellon
48
Bank of New York Mellon
New York
-$149K -70,458 Closed
N
49
Nuveen
North Carolina
-$98K -53,840 Closed
Walleye Capital
50
Walleye Capital
New York
-$110K -52,273 Closed

APLT Hedge Fund Activity: Q2 2022 in Review

53 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q2 2022, worth a combined $21.6M — down 17% from $26M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of APLT and 10 opened new positions — a net loss of 16 holders — while 20 trimmed existing stakes and 14 added.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $7.13M. The largest seller was BlackRock, cutting an estimated $1.43M.

  • 53 institutional investors held Applied Therapeutics (APLT) as of Q2 2022, down from 71 in Q1 2022.
  • Funds reported $21.6M of Applied Therapeutics stock for Q2 2022, down 17% quarter-over-quarter.
  • 10 funds opened new Applied Therapeutics positions in Q2 2022 and 26 closed out, a net change of -16 holders.
  • The largest Applied Therapeutics buyer in Q2 2022 was Alyeska Investment Group, an estimated $7.13M added.
  • The largest Applied Therapeutics seller in Q2 2022 was BlackRock, an estimated $1.43M sold.

Based on aggregated 13F filings for Q2 2022.